Effect of hospitalization and antimicrobial therapy on antimicrobial resistance of colonizing Staphylococcus epidermidis

Wiener klinische Wochenschrift
Ariane KnauerChristoph Wenisch

Abstract

Endogenous infections with multi-resistant S. epidermidis are among the leading causes of nosocomial infections. The effect of hospitalization and antimicrobial therapy on antimicrobial resistance of colonizing staphylococci was determined from swabs of the nose, hand, axilla and groin from 157 patients on one day. Hospitalization for >72 hours, compared with <72 hours, was associated with a higher percentage of isolates resistant to oxacillin (56% versus 19%), gentamicin (40% versus 15%), trimethoprim (36% versus 17%), clindamycin (56% versus 17%), and fusidic acid (20% versus 4%; p < 0.01 for all), but not to rifampicin (6% versus 1%) or fosfomycin (43% versus 34%, p > 0.05 for both). Concurrent antimicrobial therapy resulted in increased resistance to oxacillin (61% versus 28%), gentamicin (43% versus 20%), and clindamycin (60% versus 26%; p < 0.01 for all), but not to trimethoprim (39% versus 23%), fusidic acid (19% versus 9%), rifampicin (6% versus 3%), or fosfomycin (46% versus 38%, p > 0.05 for all). The increase in resistant isolates was not independent, since hospitalization and antimicrobial therapy were correlated (p < 0.001). After adjustment for potential risk factors such as diabetes mellitus, central venous cathe...Continue Reading

References

Jun 1, 1974·The Journal of Infectious Diseases·R AlyW G Strauss
Jul 31, 1974·Annals of the New York Academy of Sciences·H R ShinefieldH Maibach
Apr 1, 1974·American Journal of Diseases of Children·R AlyA D Mandel
Nov 1, 1983·Reviews of Infectious Diseases·J E McGowan
Jan 1, 1994·Clinical Microbiology Reviews·W E Kloos, T L Bannerman
Oct 1, 1995·The Journal of Hospital Infection·R P Wenzel
Jan 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L A HerwaldtM A Pfaller
Mar 1, 1997·Journal of Clinical Microbiology·F I WeinbaumS S Mills
Feb 5, 2000·The Journal of Hospital Infection·J Verhoef, R Gupta
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·M LipsitchB R Levin
Jul 6, 2000·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·D Pittet
Dec 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S K Fridkin
Jan 3, 2001·The New England Journal of Medicine·R P Wenzel, M B Edmond
Jan 4, 2001·The New England Journal of Medicine·C von EiffG Peters
Apr 11, 2001·Emerging Infectious Diseases·E Larson
Apr 11, 2001·Emerging Infectious Diseases·D Pittet
Apr 11, 2001·Emerging Infectious Diseases·R GaynesJ Tolson
May 8, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C von EiffG Peters
Jan 5, 2002·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R GeiselH Labischinski
Jan 5, 2002·The Journal of Hospital Infection·D Pittet
Jan 22, 2002·Akusherstvo i ginekologii︠a︡·S BozhinovaV Porozhanova
Mar 29, 2002·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Didier Pittet
Apr 25, 2002·Emerging Infectious Diseases·Marc Lipsitch, Matthew H Samore
Aug 6, 2002·The Journal of Antimicrobial Chemotherapy·Michael Weinbren, Keith Struthers
Sep 13, 2002·Seminars in Respiratory Infections·Franco ParadisiMarta Benedetti
Sep 26, 2002·Nutrition·Jean Vincent
Dec 4, 2002·American Journal of Infection Control·UNKNOWN National Nosocomial Infections Surveillance System
Jan 8, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin J Wood, Robert C Moellering
Jan 28, 2003·Drug Discovery Today·Joanna Coast, Richard D Smith
Apr 5, 2003·Wiener klinische Wochenschrift·Petra GastmeierHenning Rüden
May 3, 2003·The Lancet Infectious Diseases·Didier Pittet, John M Boyce
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Scott K Fridkin
Jun 20, 2003·Lancet·Jean-Louis Vincent
Jul 16, 2003·Current Opinion in Infectious Diseases·Jean-Louis Vincent, Frédérique Jacobs
Jul 16, 2003·Current Opinion in Infectious Diseases·Didier Pittet

❮ Previous
Next ❯

Citations

Nov 30, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·E AhlstrandB Söderquist
Aug 22, 2008·Annals of Clinical Microbiology and Antimicrobials·Yeliz GençYunus Bekdemir
Oct 13, 2005·Expert Opinion on Pharmacotherapy·Michael J Sladden, Graham A Johnston

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.